In draft guidance issued today for consultation, NICE has asked Lundbeck to provide more information about its drug vortioxetine hydrobromide (Brintellix) for treating major depressive episodes in adults. 

Major depressive disorder is estimated to affect between 5% and 10% of people seen in primary care, 10% to 14% of medical inpatients and up to 15% of older people.

It often has a remitting and relapsing course and is characterised by a low mood and loss of interest usually accompanied by symptoms including low energy, change in appetite, weight or sleep pattern; poor concentration; feelings of guilt or worthlessness and suicidal ideas. In severe disease, psychotic symptoms such as hallucination or delusion may be present.

Commenting on the draft guidance, Professor Carole Longson, Director of the Health Technology Evaluation Centre at NICE, said: “Major depressive disorder is relatively common and can impair a person’s social life and ability to work, as well as have a negative impact on the lives of their families and carers.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-asks-for-more-information-on-vortioxetine-brintellix-for-major-depressive-disorder